| 1 |
32791996 | Nadir CA-125 serum levels during neoadjuvant chemotherapy and no residual tumor at interval debulking surgery predict prognosis in advanced stage ovarian cancer. | 2020 Aug 13 |
1 |
| 2 |
29041009 | FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125. | 2017 |
1 |
| 3 |
16527339 | Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. | 2006 Aug |
1 |
| 4 |
9288793 | Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells. | 1997 Sep 1 |
1 |